BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 7775129)

  • 1. Postincubation with aclarubicin reverses topoisomerase II mediated DNA cleavage, strand breaks, and cytotoxicity induced by VP-16.
    Petersen LN; Jensen PB; Sørensen BS; Engelholm SA; Spang-Thomsen M
    Invest New Drugs; 1994; 12(4):289-97. PubMed ID: 7775129
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage.
    Jensen PB; Sørensen BS; Demant EJ; Sehested M; Jensen PS; Vindeløv L; Hansen HH
    Cancer Res; 1990 Jun; 50(11):3311-6. PubMed ID: 2159380
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II.
    Jensen PB; Jensen PS; Demant EJ; Friche E; Sørensen BS; Sehested M; Wassermann K; Vindeløv L; Westergaard O; Hansen HH
    Cancer Res; 1991 Oct; 51(19):5093-9. PubMed ID: 1655244
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline aclarubicin.
    Holm B; Jensen PB; Sehested M; Hansen HH
    Cancer Chemother Pharmacol; 1994; 34(6):503-8. PubMed ID: 7923561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel use for the comet assay: detection of topoisomerase II inhibitors.
    Salti GI; Das Gupta TK; Constantinou AI
    Anticancer Res; 2000; 20(5A):3189-93. PubMed ID: 11062742
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells.
    Nagata T; Higashigawa M; Shimono Y; Cao DC; Yan Mao X; M'soka T; Inamochi H; Hori H; Kawasaki H; Sakurai M
    J Exp Clin Cancer Res; 1998 Dec; 17(4):435-42. PubMed ID: 10089064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular effects of topoisomerase II inhibitors in AML cell lines: correlation of apoptosis with topoisomerase II activity but not with DNA damage.
    Gieseler F; Bauer E; Nuessler V; Clark M; Valsamas S
    Leukemia; 1999 Nov; 13(11):1859-63. PubMed ID: 10557063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Different modes of anthracycline interaction with topoisomerase II. Separate structures critical for DNA-cleavage, and for overcoming topoisomerase II-related drug resistance.
    Jensen PB; Sørensen BS; Sehested M; Demant EJ; Kjeldsen E; Friche E; Hansen HH
    Biochem Pharmacol; 1993 May; 45(10):2025-35. PubMed ID: 8390259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficient induction of chromosome-type aberrations by topoisomerase II inhibitors closely associated with stabilization of the cleavable complex in cultured fibroblastic cells.
    Suzuki H; Ikeda T; Yamagishi T; Nakaike S; Nakane S; Ohsawa M
    Mutat Res; 1995 May; 328(2):151-61. PubMed ID: 7739599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
    Sehested M; Jensen PB
    Biochem Pharmacol; 1996 Apr; 51(7):879-86. PubMed ID: 8651936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I.
    Sørensen BS; Jensen PB; Sehested M; Jensen PS; Kjeldsen E; Nielsen OF; Alsner J
    Biochem Pharmacol; 1994 Jun; 47(11):2105-10. PubMed ID: 8010996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
    Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
    Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tirapazamine: a hypoxia-activated topoisomerase II poison.
    Peters KB; Brown JM
    Cancer Res; 2002 Sep; 62(18):5248-53. PubMed ID: 12234992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Topoisomerase II-mediated DNA cleavage activity induced by ellipticines on the human tumor cell line N417.
    Multon E; Riou JF; LeFevre D; Ahomadegbe JC; Riou G
    Biochem Pharmacol; 1989 Jul; 38(13):2077-86. PubMed ID: 2544183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
    Epstein RJ; Smith PJ
    Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
    de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
    Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors.
    Dubrez L; Goldwasser F; Genne P; Pommier Y; Solary E
    Leukemia; 1995 Jun; 9(6):1013-24. PubMed ID: 7596166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfection of a human topoisomerase II alpha gene into etoposide-resistant human breast tumor cells sensitizes the cells to etoposide.
    Asano T; An T; Zwelling LA; Takano H; Fojo AT; Kleinerman ES
    Oncol Res; 1996; 8(3):101-10. PubMed ID: 8823806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modulation of 4'-(9-acridinylamino)methanesulfon-m-anisidide-induced, topoisomerase II-mediated DNA cleavage by gossypol.
    Adlakha RC; Ashorn CL; Chan D; Zwelling LA
    Cancer Res; 1989 Apr; 49(8):2052-8. PubMed ID: 2539251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Topoisomerase-II-mediated lesions in nascent DNA: comparison of the effects of epipodophyllotoxin derivatives, VM-26 and VP-16, and 9-anilinoacridine derivatives, m-AMSA and o-AMSA.
    Woynarowski JM; Sigmund RD; Beerman TA
    Biochim Biophys Acta; 1988 May; 950(1):21-9. PubMed ID: 2833925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.